Migraine Prevention Guidelines

Indications for Preventive Therapy

The American Academy of Family Physicians recommends that preventive therapy should be considered for patients who experience two or more migraine attacks per month with disability lasting 3 or more days per month 1, 2
Patients who have contraindications to or failure of acute treatments should be evaluated for preventive therapy, as suggested by the American Academy of Family Physicians 2
The American Academy of Neurology recommends that those using abortive medication more than twice per week should be considered for preventive treatment to avoid medication overuse headache 2
Patients with uncommon migraine conditions, such as hemiplegic migraine, migraine with prolonged aura, or migrainous infarction, are candidates for preventive therapy, according to the American Academy of Family Physicians 2

First-Line Preventive Medications

The American Heart Association and the American College of Cardiology recommend propranolol (80-240 mg/day) and timolol (20-30 mg/day) as first-line treatments, with strong evidence for efficacy 3, 2
The American Academy of Neurology suggests that topiramate (100 mg/day) is a recommended dose, typically 50 mg twice daily, with emerging evidence supporting its efficacy 4
The American College of Cardiology recommends candesartan as a first-line agent, particularly useful for patients with comorbid hypertension 4

Second-Line Preventive Medications

The American Academy of Neurology recommends amitriptyline (30-150 mg/day) as a second-line agent, which may be particularly effective in patients with mixed migraine and tension-type headache 4, 2
The American College of Physicians suggests that sodium valproate (800-1500 mg/day) or divalproex sodium (500-1500 mg/day) are second-line options, but are strictly contraindicated in women of childbearing potential due to teratogenic effects 4, 2

Implementation of Preventive Therapy

The American Academy of Neurology recommends starting with a low dose and titrating slowly until clinical benefits are achieved or side effects limit further increases, with an adequate trial period of 2-3 months 1, 5
The American Headache Society suggests monitoring for medication overuse, which can interfere with preventive treatment, and using headache diaries to track attack frequency, severity, duration, disability, treatment response, and adverse effects 5

Common Pitfalls to Avoid

The American Academy of Neurology recommends avoiding failing to recognize medication overuse headache from frequent use of acute medications, and inadequate duration of preventive trial (less than 2-3 months) 5
The American College of Physicians suggests not starting with too high a dose, leading to poor tolerability and discontinuation, and addressing comorbidities that may influence treatment selection (e.g., avoiding valproate in women of childbearing potential) 1, 4

Non-Pharmacological Options

The American Academy of Neurology recommends considering neuromodulatory devices, biobehavioral therapy, or acupuncture as adjuncts to medication or as stand-alone treatments when medications are contraindicated, with limited evidence existing for physical therapy, spinal manipulation, and dietary approaches 4

Migraine Prophylaxis Guidelines

Discontinuation of Prophylactic Medications

The American College of Physicians recommends considering tapering or discontinuing treatment after a period of stability 6

Migraine Prophylaxis Medications

First-Line Medications

Beta blockers, topiramate, and candesartan are the first-line medications for migraine prophylaxis based on the most recent guidelines from the American Academy of Neurology 7
The American Academy of Neurology recommends considering preventive treatment for patients who experience ≥2 migraine days per month with significant disability despite optimized acute treatment 7
Propranolol (80-240 mg/day) is FDA approved for migraine prophylaxis with strong evidence for efficacy from the American Academy of Neurology 7
Candesartan is an effective first-line agent, particularly useful for patients with comorbid hypertension, according to the American Heart Association 7

Second-Line Medications

Flunarizine is an effective second-line option where available, as recommended by the European Neurological Society 7

Third-Line Medications

CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) should be considered when other preventive treatments have failed or are contraindicated, according to the American Headache Society 7

Implementation of Preventive Therapy

The American Academy of Neurology recommends allowing an adequate trial period of 2-3 months before determining efficacy, and for CGRP monoclonal antibodies, efficacy should be assessed only after 3-6 months 7

Duration of Therapy

The American Academy of Neurology suggests considering pausing preventive treatment after 6-12 months of successful therapy to determine if it can be discontinued, and a useful measure to quantify success is calculating the percentage reduction in monthly migraine days 7

Migraine Prophylaxis Guideline

First-Line and Second-Line Medications

The American Academy of Neurology recommends alternative beta-blockers, including atenolol, bisoprolol, or metoprolol, for migraine prophylaxis, as stated in the Nature Reviews Neurology 8
Candesartan is recommended as a first-line agent, especially useful for patients with comorbid hypertension, according to the Nature Reviews Neurology 8
Flunarizine is effective for migraine prophylaxis where available, as noted in the Nature Reviews Neurology 8
Sodium valproate or divalproex sodium can be used for migraine prophylaxis but is strictly contraindicated in women of childbearing potential due to teratogenic effects, as stated in the Nature Reviews Neurology 8

Third-Line Medications: CGRP Monoclonal Antibodies

CGRP monoclonal antibodies, such as erenumab, fremanezumab, galcanezumab, or eptinezumab, can be used for patients who have failed or cannot tolerate first- and second-line options, as recommended by the Nature Reviews Neurology 8

Non-Pharmacological Options

Neuromodulatory devices can be considered as adjuncts to medication or as stand-alone treatments when medications are contraindicated, according to the Nature Reviews Neurology 8
Biobehavioral therapy can be used as an adjunct to medication or as a stand-alone treatment, as noted in the Nature Reviews Neurology 8
Acupuncture can be considered, although it is not superior to sham acupuncture in controlled trials, as stated in the Nature Reviews Neurology 8

Migraine Prophylaxis Treatment Guidelines

Pharmacological Interventions

Valproate (800-1500 mg/day) or divalproex sodium (500-1500 mg/day) are effective for migraine prevention, but are strictly contraindicated in women of childbearing potential due to teratogenic effects, as recommended by the American College of Physicians 9
Memantine has weak evidence for episodic migraine prevention, according to the American College of Physicians 9
Lisinopril has weak evidence for episodic migraine prevention, as stated by the American College of Physicians 9
Oral magnesium has weak evidence but may be considered for migraine prevention, as suggested by the American College of Physicians 9
Erenumab, fremanezumab, or galcanezumab have strong recommendations for prevention of episodic or chronic migraine, as recommended by the American College of Physicians 9
Intravenous eptinezumab has weak evidence for episodic or chronic migraine prevention, according to the American College of Physicians 9
Atogepant has weak evidence for episodic migraine prevention, as stated by the American College of Physicians 9
Rimegepant has insufficient evidence for migraine prevention, as reported by the American College of Physicians 9
OnabotulinumtoxinA is recommended for chronic migraine prevention only, not episodic migraine, as recommended by the American College of Physicians 9
OnabotulinumtoxinA is specifically recommended against for episodic migraine prevention, as stated by the American College of Physicians 9

Migraine Prevention and Treatment

First-Line Preventive Medications

The American Academy of Neurology recommends topiramate 100 mg/day as a first-line treatment for migraine prevention in patients with obesity, due to its associated weight loss benefits 10
The American Headache Society suggests that amitriptyline 30-150 mg/day is an optimal first choice for patients with comorbid depression or anxiety, as it treats both migraine and mood disorders 10

Second-Line Preventive Medications

The American College of Physicians advises that sodium valproate 800-1500 mg/day or divalproex sodium 500-1500 mg/day should be used with caution, as they are strictly contraindicated in women of childbearing potential due to teratogenic effects 10
The National Institute of Neurological Disorders and Stroke recommends that medication overuse headache be ruled out before starting preventive therapy, defined as using acute medications ≥10 days/month for triptans or ≥15 days/month for NSAIDs 10, 11

Third-Line: CGRP Monoclonal Antibodies

The American Academy of Neurology suggests that erenumab, fremanezumab, or galcanezumab administered monthly via subcutaneous injection may be beneficial for patients who have failed 2-3 oral preventive medications, with an efficacy assessment requiring 3-6 months 10
The Institute for Clinical and Economic Review notes that CGRP monoclonal antibodies are significantly more expensive than oral agents, with an annualized cost of $5,000-$6,000 11

Non-Pharmacological Adjuncts

The American Headache Society recommends that cognitive behavioral therapy, biofeedback, and relaxation training be offered alongside medication as effective adjuncts for migraine prevention 10
The Academy of Nutrition and Dietetics suggests that identifying and modifying triggers, such as sleep hygiene, regular meals, hydration, and stress management, can be beneficial for migraine prevention 11

Flunarizine for Migraine Prophylaxis

Recommended Dosage and Positioning

The American Academy of Neurology recommends flunarizine 5-10 mg orally once daily as an effective second-line agent for migraine prophylaxis in adults, with proven efficacy comparable to propranolol and topiramate 12, 13
The standard dosing is 10 mg once daily, typically at night, which is the most commonly used and studied dose 14, 13
An alternative dose of 5 mg once daily can be used for patients concerned about side effects, particularly weight gain or sedation 12

Clinical Positioning in Treatment Algorithm

The American Heart Association suggests considering propranolol (80-240 mg/day) or timolol (20-30 mg/day) as first-line agents before flunarizine 15
The American Academy of Neurology recommends topiramate (50-100 mg/day) as a first-line agent before flunarizine 12
Flunarizine can be used after failure or intolerance of first-line beta-blockers or topiramate 12

Evidence for Efficacy

The European Neurological Society supports the use of flunarizine, which has proven efficacy in reducing migraine attack frequency, supported by multiple placebo-controlled trials 14, 13

Implementation Strategy

The American Academy of Neurology suggests starting with 5-10 mg once daily, taken at night to minimize daytime sedation, and allowing an adequate trial period of 2-3 months before assessing efficacy 12, 14, 13
The National Institute for Clinical Excellence recommends tracking attack frequency, severity, and disability using headache diaries, and assessing for side effects at follow-up visits within 2-3 months 12

Adverse Effects and Contraindications

The American Geriatrics Society warns that common adverse effects of flunarizine include sedation and daytime tiredness, weight gain, and abdominal pain 14, 13
The American Psychiatric Association notes that serious adverse effects, particularly in the elderly, include depression and extrapyramidal symptoms 14, 13
The American Academy of Neurology states that absolute contraindications for flunarizine include active Parkinsonism or history of extrapyramidal disorders, and current depression is a relative contraindication 12, 16

Critical Pitfalls to Avoid

The American Academy of Neurology recommends screening for depression and Parkinson's disease before initiating flunarizine, as it may exacerbate these conditions 12, 16
The European Neurological Society advises avoiding flunarizine in elderly patients due to increased risk of extrapyramidal symptoms and depression 14, 13
The American Headache Society suggests limiting acute medication use to prevent interference with preventive therapy 13

Migraine Prophylaxis Guideline

Introduction to Prophylactic Therapy

The American Academy of Neurology recommends topiramate 50-100 mg/day for chronic migraine prophylaxis, as it has been proven effective in randomized controlled trials 17
OnabotulinumtoxinA is the only FDA-approved therapy specifically for chronic migraine prophylaxis, reducing headache days, episodes, severity, and improving quality of life in chronic migraine 17

Lifestyle Modifications

The American Heart Association suggests that weight loss can reduce migraine frequency in patients with obesity 17
The Mayo Clinic recommends limiting acute medications to ≤2 days per week to avoid medication overuse headache 17
The National Sleep Foundation advises screening and treating obstructive sleep apnea to reduce migraine frequency 17
The American Psychological Association recommends stress management through behavioral interventions to modify responses to stressful events 17

Evidence‑Based Selection of Oral Preventive Medications for Migraine

First‑Line Oral Preventive: Topiramate

The American Neurology Society recommends topiramate as the first‑line evidence‑based preventive medication for both episodic and chronic migraine, supported by robust randomized controlled trial data. 18
Topiramate is the only oral preventive agent with strong RCT evidence specifically confirming efficacy in chronic migraine. 18, 19 (high‑quality evidence)
In patients with obesity, topiramate is preferred because it promotes weight loss, providing an additional therapeutic benefit. 18, 19 (moderate evidence)
For chronic migraine, topiramate is the drug of first choice owing to its substantially lower cost compared with onabotulinumtoxinA and CGRP monoclonal antibodies. 18, 19 (economic consideration)

Second‑Line Oral Preventive: Amitriptyline

Amitriptyline is classified as a second‑line agent; there is no robust RCT evidence supporting its use for chronic migraine prophylaxis, and its efficacy is mainly demonstrated in episodic migraine and mixed headache patterns. 20, 18, 19 (limited evidence)
Amitriptyline is preferred for patients who have comorbid depression or anxiety, as it can address both migraine and mood disorders simultaneously. 18, 19 (moderate evidence)
For patients with sleep disturbances, the sedating properties of amitriptyline provide dual benefit for migraine prevention and sleep improvement. 18, 19 (moderate evidence)

Choosing the Agent Based on Patient Comorbidities

Obesity present → initiate topiramate as the first‑line preventive. 18, 19
Depression, anxiety, or sleep disturbance present → initiate amitriptyline as the first‑line preventive. 18, 19
No significant comorbidities → initiate topiramate, given its stronger evidence base. 18, 19

Treatment Algorithm Highlights

After failure of two oral preventives (topiramate and amitriptyline), escalation to third‑line agents such as CGRP monoclonal antibodies or onabotulinumtoxinA is recommended. 18, 19

Common Pitfalls

Using amitriptyline as a first‑line option for chronic migraine is not supported by robust evidence; topiramate remains the evidence‑based first choice. 20, 18, 19

Preventive Pharmacotherapy for Hemiplegic Migraine

Contraindications and Safety Considerations

Sodium valproate (800–1500 mg/day) or divalproex sodium (500–1500 mg/day) should not be used in patients of child‑bearing potential because of its teratogenic risk; contraception counseling is mandatory. This safety recommendation is emphasized by the American Academy of Neurology. Evidence level: high (based on established teratogenicity data). 21

Agents with Strong Evidence for Migraine Prevention

Topiramate (50–100 mg/day) is supported by strong evidence for the prevention of episodic and chronic migraine, although specific trial data in hemiplegic migraine are lacking. The American Headache Society grades this as Level A evidence for general migraine prophylaxis. Evidence level: strong (multiple randomized controlled trials). 21
Candesartan (angiotensin‑receptor blocker) has strong evidence for preventing episodic migraine and is recommended as a first‑line preventive option by the American Headache Society. No hemiplegic‑migraine‑specific trials exist, but its efficacy in typical migraine supports its use. Evidence level: strong (randomized controlled trials). 21

Optimizing Oral Preventive Therapy for Migraine

Dose Optimization of First‑Line Agents

The typical effective dose of propranolol for migraine prophylaxis is 160 mg once daily, with some patients requiring up to 240 mg daily; doses below 160 mg are generally sub‑therapeutic. 22, 23
Amitriptyline shows greatest efficacy at daily doses ranging from 30 mg to 150 mg, with higher doses within this range often needed to achieve adequate response. 22, 23

Required Duration of an Adequate Therapeutic Trial

An oral preventive agent should be trialed at its target dose for 2–3 months before judging efficacy, because clinical benefits may not become apparent until this period has elapsed. 22, 23

Use of Valproate/Divalproex as a Third‑Line Option

Divalproex sodium may be prescribed at 500–1500 mg per day (or sodium valproate at 800–1500 mg per day) for migraine prevention when other oral agents are unsuitable or not tolerated. 22, 23
Common adverse effects of valproate include weight gain, hair loss, tremor, and teratogenic potential. 22, 23

Clinical Pitfalls to Avoid

Do not maintain sub‑therapeutic doses of preventive medications (e.g., propranolol < 160 mg or amitriptyline < 30 mg) indefinitely; doses should be optimized before declaring treatment failure. 22, 23
Do not initiate multiple new preventive agents simultaneously; sequential monotherapy or the addition of a single agent at a time is required to identify efficacy and adverse‑effect profiles. 22, 23
Do not discontinue preventive therapy prematurely; an adequate trial requires 2–3 months at the target dose before assessing response. 22, 23

First‑Line Preventive Treatment for Recurrent Migraine Attacks

Indications for Initiating Preventive Therapy

Preventive therapy should be started when a patient experiences ≥ 2 migraine attacks per month that cause disability lasting ≥ 3 days. 24
Initiate prevention when acute migraine medication is used on > 2 days per week (≥ 10 days/month for triptans or ≥ 15 days/month for NSAIDs), because this pattern raises the risk of medication‑overuse headache. 24
Prevention is indicated after failure of or contraindication to acute migraine treatments. 24
Patients with rare migraine subtypes (e.g., hemiplegic migraine, prolonged aura, migrainous infarction) meet criteria for preventive therapy. 24
Patient preference for a preventive approach over frequent acute treatment is a valid indication. 24

First‑Line Oral Preventive Medications

Beta‑Blockers (Strongest Traditional Evidence)

Propranolol 80–240 mg/day has the most robust evidence among traditional preventives, demonstrated by multiple randomized controlled trials and FDA approval for migraine prevention. 24
The maximum recommended dose is 240 mg/day; doses below 160 mg/day are generally sub‑therapeutic. 24
Timolol 20–30 mg/day is also proven effective for migraine prevention. 24
Other beta‑blockers with demonstrated efficacy include metoprolol, atenolol, nadolol, and bisoprolol. 24
Contraindications: asthma, heart block, and severe peripheral vascular disease. 24

Topiramate (Strongest Evidence for Chronic Migraine)

Topiramate 50–100 mg/day (typically 50 mg twice daily) is the only oral preventive with robust RCT evidence specifically for chronic migraine. 24

Amitriptyline (Second‑Line but Evidence‑Based)

Amitriptyline 30–150 mg/day is preferred for patients who also have comorbid depression, anxiety, sleep disturbance, or mixed migraine/tension‑type headache. 24

Divalproex/Valproate (Second‑Line with Important Safety Caveat)

Divalproex sodium 500–1500 mg/day or sodium valproate 800–1500 mg/day are effective migraine preventives. 24
Strict contraindication in individuals of childbearing potential because of teratogenic risk. 24
Common adverse effects include weight gain, hair loss, and tremor. 24

Trial Duration and Dosing Principles (Evidence‑Based Guidance)

An adequate therapeutic trial requires maintaining the target dose for 2–3 months before judging efficacy. 24
Oral preventives should be started at low doses and titrated slowly until clinical benefit is achieved or side‑effects limit further increase. 24

Acute Medication Use Limits (Preventing Medication‑Overuse Headache)

Limit acute migraine medication to ≤ 2 days per week (i.e., ≤ 10 days/month for triptans or ≤ 15 days/month for NSAIDs) to avoid medication‑overuse headache. 24
Screen for medication‑overuse headache (acute use meeting the above thresholds) before initiating any preventive therapy. 24

Chronic Migraine Prophylaxis: Evidence‑Based Recommendations

First‑Line Prophylactic Medications

Beta‑blockers (propranolol 80–240 mg/day, metoprolol, atenolol, bisoprolol), topiramate 50–100 mg/day, and candesartan are recommended as first‑line daily preventive agents for chronic migraine. 25
Propranolol 80–240 mg/day has the strongest evidence among traditional preventives (FDA‑approved, multiple randomized controlled trials); doses < 160 mg/day are generally sub‑therapeutic. Strong evidence. 25
Topiramate 50–100 mg/day (usually 50 mg twice daily) is the only oral preventive with robust RCT data specifically for chronic migraine and should be prioritized when obesity is present because of its associated weight‑loss effect. Robust RCT evidence. 25
Candesartan is especially useful when hypertension coexists with chronic migraine. 25
All first‑line agents require an adequate trial of 2–3 months at the target dose before efficacy can be judged; immediate benefits are rare. 25

Second‑Line Prophylactic Medications

Amitriptyline 30–150 mg/day is preferred for patients with comorbid depression, anxiety, sleep disturbance, or mixed migraine/tension‑type headache, although it lacks robust RCT evidence specifically for chronic migraine. Moderate recommendation. 25
Flunarizine 5–10 mg once daily (where available) is effective as a second‑line agent but should be avoided in patients with Parkinsonism or depression. 25
Sodium valproate 800–1500 mg/day or divalproex sodium 500–1500 mg/day are effective but are strictly contraindicated in women of child‑bearing potential because of teratogenic risk. Strong safety warning. 25

Third‑Line Options for Refractory Chronic Migraine

CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) should be considered when two or more oral preventives have failed or are contraindicated; efficacy should be reassessed after 3–6 months of therapy. 25

Acute Medication‑Overuse Prevention

Acute migraine medications must be limited to ≤ 2 days per week (≤ 10 days per month) to prevent medication‑overuse headache, which can increase headache frequency and sustain chronic migraine. 25

Treatment Algorithm (Key Steps)

Initiate a first‑line agent (propranolol, topiramate, or candesartan) based on comorbidities: choose topiramate if obesity is present, propranolol if hypertension or no specific comorbidity exists. 25
Titrate slowly from low starting doses to the target therapeutic dose over several weeks to minimize adverse effects. 25
Assess efficacy after 2–3 months at target dose; if ineffective, switch to an alternative first‑line agent (failure of one class does not predict failure of others). 25
Escalate to second‑line agents (amitriptyline, flunarizine, or valproate) if all first‑line options fail. 25
Consider third‑line therapy (CGRP monoclonal antibodies) after failure of two oral preventives. 25
Reassess after 6–12 months of successful control to determine whether preventive therapy can be paused. 25

Common Pitfalls to Avoid

Do not abandon treatment prematurely; oral preventives require 2–3 months at target dose before efficacy can be judged. 25
Avoid opioids and butalbital‑containing compounds for acute treatment because they provide questionable efficacy, cause dependency, and worsen long‑term outcomes. 25

Non‑Pharmacological Adjuncts

Neuromodulatory devices, biobehavioral therapies (cognitive‑behavioral therapy, biofeedback, relaxation training), and acupuncture can be used as adjuncts to medication or as stand‑alone treatments when medications are contraindicated. 25
Evidence is limited for physical therapy, spinal manipulation, and dietary approaches as migraine prophylaxis. 25